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Marrying synthetic biology with synthetic chemistry provides a powerful approach
toward natural product diversiﬁcation, combining the best of both worlds: expediency
and synthetic capability of biogenic pathways and chemical diversity enabled by
organic synthesis. Biosynthetic pathway engineering can be employed to insert a chemically
orthogonal tag into a complex natural scaffold affording the possibility of site-selective
modiﬁcation without employing protecting group strategies. Here we show that, by installing
a sufﬁciently reactive handle (e.g., a C–Br bond) and developing compatible mild aqueous
chemistries, synchronous biosynthesis of the tagged metabolite and its subsequent chemical
modiﬁcation in living culture can be achieved. This approach can potentially enable many new
applications: for example, assay of directed evolution of enzymes catalyzing halo-metabolite
biosynthesis in living cells or generating and following the fate of tagged metabolites and
biomolecules in living systems. We report synthetic biological access to new-to-nature
bromo-metabolites and the concomitant biorthogonal cross-coupling of halo-metabolites in
living cultures.
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Bacterial natural products represent an unparalleled startingpoint for drug discovery1, and there is much interest inthe generation of analogs of such compounds in order to
explore modes of action, determine structure-activity-
relationships and improve bioavailability and bioactivity.
Natural products and their analogs may of course be accessed
through total synthesis; excellent recent examples include
the total synthesis of the antibiotic marinomycin2 and
generation of rifamycin and the structurally related metabolite
salinisporamycin3, 4. Such studies are invaluable in
developing methodology, revealing potential biogenic
mechanisms and providing the only access to molecules
generated by rare or hard to culture organisms. However, the
approach of total synthesis can be challenging, time consuming
and costly. Analog generation through semi-synthesis is also
limiting; with the selective chemical modiﬁcation of complex
molecules remaining as a longstanding challenge within chemical
synthesis, and usually demanding the presence of innate chemical
orthogonality within the molecule. To overcome such obstacles,
Miller has pioneered the use of peptides to catalyze site-selective
epoxidation5, acylation6 and halogenation7 of complex scaffolds,
enabling access to novel antibiotic analogs; nevertheless, a range
of regioisomers still results.
The enzymatic introduction of a halogen into a compound is
regioselective and provides a chemically orthogonal handle to
enable its further direct functionalization through cross-coupling
methodologies; we have previously developed such a
GenoChemetic strategy, but were limited in vivo to chlorination8.
Analogous to our GenoChemetic approach, Miller has combined
his peptide enabled selective bromination with diversiﬁcation
using Suzuki–Miyaura cross-coupling. This is exempliﬁed in his
regioselective functionalisation of vancomycin through a stepwise
monodehalogenation/cross-coupling strategy of its native aryl
chlorides9 and his two step derivatization of teicoplanin10. In a
complementary approach to Miller, Lewis has engineered
the halogenase RebH to enable regioselective and late-stage
in vitro bromination of synthetic scaffolds11. The use of
a membrane-partitioned reactor, to segregate a stabilized
halogenase enzyme aggregate (crosslinked enzyme aggregates
(CLEAs)) from a palladium catalyst, enabled the ‘almost
one-pot’ C-H functionalization of aryl compounds to be achieved
at 50–80 °C on a 3-indole propionate substrate12.
The cross-coupling of the highly reactive C-I bonds of
4-I-phenylalanine residues in modiﬁed proteins13 and the
cross-coupling of aryltriﬂates in living cells has also been
demonstrated14. In these studies, the aryl iodide and triﬂate
substrates utilized, were synthesized separately and exogenously
supplied.
Building upon our GenoChemetics approach to generate nat-
ural product analogues8, we wished to explore the ambitious goal
of genetically engineering the biosynthesis of a metabolite tagged
with a sufﬁciently reactive, chemically orthogonal handle. Such an
approach would allow the tagged metabolite to be a good sub-
strate for subsequent palladium-mediated modiﬁcation in
the presence of the living cells that produced it. While the
incorporation of a C–I bond provides a highly reactive site for
functionalization, so far, no enzymes capable of iodination have
been characterized and therefore other halogenases must be
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Fig. 1 Biosynthetic halogenation enabling Suzuki–Miyaura cross-coupling. a in vivo generation of Cl-pacidamycin, by the natural producer, transformed
with a halogenase, followed by in vitro cross-coupling of the compound as a component of cell free extract, at 80 °C (in vivo: in vitro)8, b in vitro generation
of reactive bromo-aromatics by RebH variant enzymes, followed by in vitro cross-coupling of the compound as a component of the crude extract (in vitro:
in vitro)11, c in vitro generation of reactive bromo-aromatics by stabilized crosslinked enzyme aggregates ((CLEAs) of a series of ﬂavin-dependent
halogenases, membrane partitioned from anaerobic, palladium-mediated cross-coupling conditions (in vitro: in vitro)12, d in vivo incorporation of reactive,
synthetic iodophenylalanine into peptides, followed by protein puriﬁcation and cross-coupling of the iodinated protein (in vivo: in vitro)13, e in vivo
Suzuki–Miyaura modiﬁcation of synthetically generated, reactive triﬂate ﬂuoran (synthetic: in vitro)14, f in vivo generation of reactive 7-Br-tryptophan 2
by engineered E. coli RG-1500 synchronous with the in-culture Suzuki–Miyaura cross-coupling of this reactive metabolite (in vivo: in vivo); and g generation
of reactive Br-pacidamycin D 3 by engineered Streptomyces coelicolor RG-1104 concomitant with the in-culture Suzuki–Miyaura cross-coupling of this
reactive metabolite (in vivo: in vivo)
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employed. The engineering of several pathways to enable the
generation of new-to-nature ﬂuoro- and chloro-metabolites
has been previously achieved8, 15–18. The C–F bond does not
facilitate subsequent cross-coupling and the poor reactivity of
C–Cl renders cross-coupling challenging as it requires harsher
conditions8. Engineering the biosynthesis of brominated natural
products represents a needed compromise between chemical
reactivity and genetic install-ability. For our model system, we
choose to focus toward diversiﬁcation of tryptophan 1. This
amino acid is a key component in many natural products and its
presence in proteins and peptides is important to their structural
integrity and ﬂuorescent properties, its modulation is therefore
attractive. Mild approaches to address the functionalization of
halo-tryptophans are challenging as halo-indoles are shown to be
less reactive than analogous heterocyclic aryl halides19.
Results
Aqueous method for mild cross-coupling of halo-indoles.
To work toward developing suitably mild and potentially cell
compatible, aqueous and aerobic conditions for Br-tryptophan
diversiﬁcation (Fig. 1), preferably at 37 °C, we ﬁrst explored
cross-coupling of Br-indoles. The cross-coupling of 5-Cl-indole 6
at 40 °C in degassed dioxane-water using K3PO4 has precedent20;
however, for potential biocompatibility, a more appropriate
solvent and atmosphere are requisites. Starting with our model
reaction of coupling of 5-I-, Br- and Cl-indole (4, 5 and 6,
respectively) with p-tolyl-boronic acid (p-Tol-B(OH)2), we
screened series of sulphonated water-soluble phosphine ligand
complexes (including triphenylphosphine-3,3′,3″-trisulfonic
acid (TPPTS), SSPhos [L1-Pd, Fig. 2], SXPhos)21, 22 and pre-
catalysts based on bidentate ligands23 such as [PdCl2(dppf)],
[PdCl2(dtbpf)], [PdCl2(Xantphos)] and NHC-Pd24 for their
ability to promote Suzuki–Miyaura cross-coupling in water and
mild base (K2CO3, Na2CO3, K3PO4 or Cs2CO3) in the presence of
air (Supplementary Fig. 1 and Supplementary Table 1). From this
initial screen, the combination of the water-soluble Na2PdCl4 and
sterically demanding, electron-rich SSPhos ligand, with K2CO3 as
base, showed greatest potential (Table 1). Notably, in the case of
5-I-indole 4, we observed that its cross-coupling can be con-
ducted in water alone, at 20 °C with a relatively low Pd-catalyst
loading (2 mol%) and 1.2 equiv. p-Tol-B(OH)2, resulting in 72%
nuclear magnetic resonance (NMR) yield after 8 h. Moreover, we
demonstrated that addition of biologically tolerable 20% v/v
CH3CN or EtOH assisted in solvating the reactants and improved
the NMR yields (90 and 92% respectively at 20 °C, 8 h,
Supplementary Table 1, entries 2 and 3) and that almost quan-
titative conversions could be achieved by increasing the tem-
perature to 37 °C (98%, 8 h, Table 1, entry 1).
Having developed very mild conditions for the cross-coupling
of 4, we investigated the cross-coupling of the less reactive
and more demanding Br- and Cl-indoles. By increasing the
Pd loading and boronic acid equivalents (5 mol% and 1.5
equiv. p-Tol-B(OH)2, respectively) high conversions for 5-Br-
and 5-Cl-indole (5 and 6, respectively) were obtained at 37 °C
after 18 and 48 h, respectively (Table 1, entries 3 and 5).
Tryptophan inhibits L1-Pd catalyzed Suzuki–Miyaura coupling.
We next investigated the cross-coupling of
halo-tryptophan using mild, aqueous conditions. We previously
reported the ﬁrst Suzuki–Miyaura cross-coupling reaction of
unprotected Br- and Cl-tryptophans, these reactions
required heating at 80 °C25. Under the optimal conditions for
halo-indoles (described above), the cross-coupling of
unprotected 5- or 7-Br-tryptophan (13 and 2, respectively) was
unsuccessful, potentially due to their ability to coordinate to Pd
and substrate could inhibit the catalysis under mild reaction
conditions10, 26. Hence, to explore the inhibition of the
cross-coupling of halo-indoles by the amino acid, we investigated
the reaction of 5-I-indole 4, doped with free tryptophan 1, with
p-Tol-B(OH)2. An almost linear drop in conversion correlated
with the increase in added tryptophan 1 (Fig. 3) was observed.
To explore whether the drop in conversion is directly attributable
to the carboxylate or primary amine functionality, we added
one equiv. of either tryptophan 1, tryptophan methyl ester 9,
N-acetyl tryptophan 10 (acylated primary amine) or the N-acetyl
tryptophan methyl ester 11 (Fig. 3). The effect of addition of
tryptophan methyl ester 9 or free tryptophan 1 on the reaction
were comparable (conversions reduced to 12 and 15%
respectively). However, in reactions where one equiv. of N-acetyl
tryptophan 10 was added, as a potential inhibitor, a 41%
conversion resulted. This indicates that the primary amine of
tryptophan plays a key role in the inhibition of the reaction;
however, the carboxylate may not be considered as completely
innocent as when doubly protected tryptophan 11 was added, a
conversion of 59% resulted under the same reaction conditions.
It is possible, therefore, that N- and O-coordination complexes
(NH2-Pd, COO-Pd) or N,O-Pd may be formed in situ, reducing
the effective concentration of available Pd for catalysis26–29.
Usefully, we observed that inhibition of cross-coupling by
tryptophan 1 can be partially reversed by increasing the
concentration of p-Tol-B(OH)2. These results indicate that
chelation of Pd by the amino acid motif is not the sole possibility;
but that heterodimeric complexation of amino acid with boronic
acid is also present30. Together, these two equilibria could
contribute towards inhibition of the cross-coupling reaction.
Suzuki–Miyaura coupling of Br-tryptophans and tripeptides.
In the light of our observations on the inhibitory effect of the
amino acid, we next set out to explore mild conditions that could
be translated to cross-coupling of unprotected halo-tryptophan
or halo-tryptophan containing peptide. We screened series of
catalysts and ligands for any that would provide reactivity at
physiological temperature (Supplementary Fig. 1). Recently,
Ballet et al.31. reported that the palladium pre-catalyst of
disodium 2-aminopyrimidine-4,6-diol31–34 (L2-Pd, Fig. 2) was
effective for cross-coupling of halo-tryptophans at 80 °C under
microwave irradiation. We further explored the utility of L2-Pd
to perform cross-coupling at lower temperature. After optimizing
reagent concentrations (3 equiv. p-Tol-B(OH)2 and 6 equiv.
K2CO3), we successfully cross-coupled unprotected 7-Br-
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Fig. 2 Selected water-soluble catalysts explored in this study. Catalyst stock
solutions were prepared in deionized water, stored at ambient temperature
and used within two weeks. L1-Pd solution were freshly prepared each day.
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tryptophan 2, at 45 °C (Fig. 4a). The reaction proceeded smoothly
using 5 mol% of the L2-Pd catalyst and the product
7-p-tolyl-tryptophan 2a was isolated in high yield (85%). For
5-Br-tryptophan 13, a 90% NMR conversion and a lower 54%
isolated yield of the product 13a, potentially due to product
solubility issues, was observed. Moreover, a modest 32%
conversion was observed for the signiﬁcantly more challenging
and less reactive unprotected 7-Cl-tryptophan 12 (Fig. 4a).
To assess the applicability of these cross-coupling conditions
for the modiﬁcation of small peptides, we explored the reaction
with three tripeptides containing 7-Br-tryptophan 2
placed centrally 14 or at the N-terminal 15 or C-terminal 16
(Fig. 4b)35 (for syntheses, see Supplementary Methods). The
reactions worked well in aqueous conditions without need for
organic co-solvent and at relatively low catalyst loading (L2-Pd, 5
mol%). The cross-coupling products 14a-16a were isolated in
good yields (62–71%, Fig. 4c). In general, this mild protocol is
amenable for derivatisation of peptides and has potential to be
applicable to higher polypetides/proteins possessing halo-aryl
functionality.
Our ultimate and ambitious goal was to, for the ﬁrst time,
enable engineered production of a halogen tagged metabolite and
its cross-coupling in living culture. This would be a signiﬁcant
breakthrough in the ﬁeld. Such a combination of genetic
engineering to generate tagged metabolites and both synchronous
and sequential chemical modiﬁcation of the tag has the exciting
potential to pave the way to in vivo diversiﬁcation, labeling
and afﬁnity tagging. To explore whether we could engineer
biosynthetic halogenation and chemical cross-coupling in a living
system, we chose to work toward two model systems of varying
challenge: ﬁrstly, engineering Escherichia coli for biosynthesis of
7-Br-tryptophan 2, secondly engineering streptomycetes to
produce Br-pacidamycin D. Pacidamycin represents a challenging
model system; its selective functionalization is inherently difﬁcult
as it contains both a peptide chain and a modiﬁed nucleic acid
moiety. Pacidamycin is produced, like many natural products, in
Table 1 Mild cross-coupling of halo-indoles
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3 5-Br (5) 18 99 92 (5a)
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5 5-Cl (6) 48 94 90 (6a)
6 7-Br (7) 20 Quant. 96 (7a)
7 7-Cl (8) 36 95 85 (8a)
Optimized reaction conditions for various halo-indoles
aConversion was determined by 1H NMR of the crude reaction
bIsolated yields are reported after ﬂash chromatography
cReaction was carried using 2 mol% of catalyst loading and 1.2 equiv. of p-Tol-B(OH)2
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Fig. 3 Tryptophan inhibits L1-Pd catalyzed cross-coupling. Inhibition of cross-coupling of 5-I-indole 4 doped with increasing concentrations of unprotected
tryptophan 1 (0–1 equiv.) or selectively protected tryptophans 9–11 (1 equiv.). Conversion was determined by 1H NMR of the crude reaction
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very low concentration and challenges any synthetic methodology
to be efﬁcient even at such high dilution. It also exempliﬁes a
further demand in accessing the bromo-metabolite because the
natural producer has poor tolerance to bromide, and the
biosynthetic gene cluster would therefore need to be introduced
into a more suitable host strain. We set out to engineer the two
systems and to systematically and iteratively address the impact
of the cross-coupling reagents on the two biological systems and
assess how components from the fermentation media would
impact upon cross-coupling efﬁciency. To undertake this
ambitious task, we ﬁrst explored and enabled the generation
and cross-coupling of 7-Br-tryptophan 2 in E. coli culture.
Applying in-culture GenoChemetics to tryptophan. A plasmid
carrying prnA encoding a tryptophan 7-halogenase from pyrrol-
nitrin biosynthesis36 was constructed and introduced into
E. coli PHL644 strain (engineered E. coli RG-1500), and upon
supplementation of the culture with sodium bromide, resulted in
production of 7-Br-tryptophan 2 (see Supplementary Figs 6–8
and Supplementary Methods for details).
We set out to establish conditions that would promote 7-Br-
tryptophan 2 production and be suitable for its corresponding
cross-coupling in living cultures of E. coli. While cross-coupling
of synthetic halogenated materials has been previously reported
in buffer37 there are no reports of reactions carried out in media
that would be required to sustain growth and metabolite
production. In parallel, we established the effect of Pd,
ligand and boronic acid concentration, both separately and in
combination, on E. coli viability; and explored the efﬁciency of
cross-coupling of 7-Br-tryptophan 2 within a range of media and
in the presence of individual media components. As an in vitro
model reaction for this screening, we used 7-Br-tryptophan 2
(0.35 mM)38, p-Tol-B(OH)2 (1.2 mM, 3.4 equiv.) and L2-Pd
catalyst (0.1 mM) (for details of the media screening see
Supplementary Discussion). In summary, key observations
revealed that only trace conversion (< 2%) occurred in the
presence of series of standard culture media (e.g., Luria-Bertani
(LB), 2xYT) or yeast/malt extracts (Supplementary Table 2).
However, we observed that cross-coupling conditions were
tolerant to phosphate buffer (100 mM with 50 mM NaCl/Br,
pH 8) and citrate buffer (100 mM, pH 8). Provision of both a
carbon and nitrogen source is essential for bacteria growth.
Nitrogen is usually supplied from amino acids and/or ammonium
salts in the media. Our investigations demonstrated both the free
amine and carboxylate of tryptophan 1 had a detrimental effect
on the reaction (discussed in earlier section). Unsurprisingly,
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cross-coupling was strongly suppressed by the presence of amino
acids (e.g., glycine 20 mM) as well as ammonium salts. Provision
of a suitable carbon source could also prove a challenge, as poor
conversions (~10%) were observed in the presence of glucose
(22 mM, 0.4% w/v) or glycerol (217 mM, 2% w/v). Alternative
carbon sources, that could either enter directly into the Krebs’
cycle (such as citrate) or could be slowly metabolized so that
inhibitory monosaccharide and glycerol concentrations would
remain low, were also explored (see Supplementary Table 2).
Following numerous iterative rounds of assessing media that
would enable bacterial growth, 7-Br-tryptophan 2 production and
be cross-coupling compatible, we determined that a minimal
media containing potassium nitrate (20 mM) as the nitrogen
source, glycerol (0.5% w/v, 55 mM) as the sole carbon source and
supplemented with 50 mM NaBr (‘cross-coupling media’ (CCM))
could be employed. Aware that the bacteria would metabolize the
media, thereby depleting the carbon and nitrogen sources initially
supplied, we also considered that a dynamic living system would
generate cofactors, bio-thiols and radical species with a potential
to poison Pd-catalyst and be detrimental to the cross-coupling
reactions. To determine the impact of such metabolites, cultures
of the engineered E. coli RG-1500 were grown and bromination of
tryptophan was performed; cells were then removed by
centrifugation and the resultant cell free supernatant media
containing in vivo generated 7-Br-tryptophan 2 (‘spent media’)
was used for further screening of the cross-coupling reactions.
Though series of metabolites that have the potential to interfere
with the catalytic cycle, chelating to the Pd have been generated,
encouragingly 82% conversion for the cross-coupling could be
achieved, if ﬁrst diluted 1:5 in phosphate buffer (Supplementary
Table 4). The reactions in the spent CCM proceeded well to give
high conversions; however, the reaction time was very long (60 h)
upon using p-Tol-B(OH)2 (1.2 mM) and L2-Pd (100 µM).
Thus, we again looked further toward a more active Pd catalyst
system. Pd-catalysts based on tetramethylguanidine (L4-Pd)39
and 2-(dimethylamino)-pyrimidine-4,6-diol (L3-Pd)40 ligands
were recently reported to enable the expeditious cross-coupling
of activated aryl iodides. Importantly, both are water-soluble and
their lack of toxicity is attractive for in vivo applications. We were
pleased to ﬁnd both ligand variants (L3-Pd, L4-Pd) afforded
increased catalytic activity with ~2-fold increase in conversions
(75% and 70% respectively) over L2-Pd catalyst (38%) using the
spent CCM (Supplementary Fig. 3). Moreover, these conversions
were obtained after 18 h using 100 µM Pd-catalyst and 1.2 mM
boronic acid at 1:4 dilution. A time course experiment at 1:8
dilution revealed complete conversion of 2 within 4 h and high
Ultra Performance Liquid Chromatography (UPLC) yields of
cross-coupling product for both L3-Pd (76%) and L4-Pd (64%)
were obtained for the spent CCM (Supplementary Fig. 4). These
results, achieved at a low Pd-concentration (50 µM) within 4 h,
represented signiﬁcant advancement towards our goal.
Having developed a suitable medium and improved catalytic
system, we cultured E. coli RG-1500 in CCM supplemented with
L-tryptophan (1.5 mM). By UPLC, we determined that optimal
7-Br-tryptophan 2 production was achieved after 24 h
(see Supplementary Fig. 7–9); at this time point, the culture
was mixed with phosphate buffer (10 mM, pH 8.5), followed by
addition of p-Tol-B(OH)2 (1 mM) and appropriate Pd-catalyst
(50 µM) and incubated for a further 4 h to obtain a conversion of
61% of the desired product 2a (Fig. 5 and Supplementary
Table 5). The slightly lower conversions of the product 2a in a
matured living culture may be due to interference from the
soluble cofactors required for halogenation as catalyzed by PrnA
(e.g., redox active NAD+/NADH system), excreted amino
acids/proteins (coordinating to Pd), carbohydrates (chelation
with boronic acid) as well as bio-thiols (Pd-poisoning).
The viability of cells was assessed by comparing the numbers
of colony forming units. The cells from the in-culture cross-
coupling remained fully viable (Supplementary Fig. 12).
Antibiotic analogue generation via in-culture GenoChemetics.
The antibiotic pacidamycin is a challenging system demanding
that any orthogonal derivatization chemistry developed must be
nucleoside and peptide compatible. We previously demonstrated
the ﬁrst out of context use of a halogenase, introducing the gene
encoding prnA to the wild-type pacidamycin producing strain
Streptomyces coeruleorubidis in order to generate a strain (RG-
5059) capable of producing chloropacidamycin8.
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Generation of the more reactive bromo-metabolite would be
essential if we were to achieve compound generation and
synthetic modiﬁcation synchronously in live culture. However,
supplementation of RG5059 culture media with various bromide
salts including KBr, NaBr, NH4Br impaired culture growth
and no brominated pacidamycin could be detected; it was clear
that the natural pacidamycin producer could not be utilized for
the generation of brominated metabolites. We investigated the
tolerance of another streptomycete, S. coelicolor M115441, to
bromide salts (from 0 to 200 mM in 50 mM increments) and
determined 100 mM KBr to be well tolerated. Next, we
engineered the heterologous production of pacidamycin into
this strain by conjugatively transforming the strain with
S. coeruleorubidus cosmid 2H-542, which carries
pac1-pac22 as a 32.2 kb insert. This new synthetic strain (named
RG-4242) was shown to produce pacidamycin, and its growth
and production of pacidamycin not be compromised by bromide
salts. Next, we installed prnA, encoding tryptophan 7-halogenase,
into the genome (see Supplementary Methods and Supplemen-
tary Figs 13–15), resulting in engineered strain RG-1104. Cultures
of RG-1104 grown in the presence of sodium bromide (50/100
mM) were demonstrated to produce Br-pacidamycin D 3
by liquid chromatography-mass spectrometry (LC-MS;
Supplementary Figs 19–21).
Having utilized a synthetic biological approach to generate a
strain capable of producing new-to-nature bromo-metabolites,
the stage was set to determine whether synchronous biosynthetic
bromo-natural product production and chemical diversiﬁcation
in living bacterial culture could be accomplished. This system
further challenged the limits of the technology with the
S. coelicolor culture being considerably more susceptible to
palladium poisoning than the E. coli culture and the metabolic
proﬁle being rather more complex. Exploring the media (CCM)
that was developed for the cross-coupling of 2 (Fig. 5) in living
cultures of E. coli, we observed that it was both capable of
supporting the growth of S. coelicolor (RG-1104) and production
of Br-pacidamycin D 3 (Fig. 6). To implement the cross-coupling
in the presence of the living cells, a mature (6 day old) culture
grown in CCM was mixed with phosphate buffer, followed
by addition of p-Tol-B(OH)2 and appropriate L3-Pd/L4-Pd
solutions and incubated at 37 °C, 25 μM Palladium and 1 mM
boronic acid proved to be optimal. The reaction mixture was
analyzed after 4 h by LC-MS, revealing the complete consumption
of Br-pacidamycin-D 3 and presence of the desired product
p-tolyl-pacidamycin D 3a (Fig. 6 and Supplementary Figs 23–25).
Again, we explored the viability of the engineered cells following
the reaction and quenching with DTT at 4 h, little impact on the
cell viability could be observed for L4-Pd (> 96% viability
Supplementary Fig. 26).
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Discussion
In summary, we have developed, in two different systems,
the ﬁrst synthetic biological generation of new-to-nature
bromo-metabolites and their synchronous cross-coupling within
a living aerated microbial fermentation, even at high dilution.
As many natural products are generated at low concentration,
this is essential. This pioneering approach and exceptionally mild
conditions for Suzuki–Miyaura cross-coupling of challenging
halo-metabolites have the potential to be broadly used for the
GenoChemetic diversiﬁcation of halogenated natural products
and new-to-nature halo-natural products. This approach is
powerful as it enables the generation and diversiﬁcation of a
natural product in the presence of the cells that produce it. Being
able to perform this chemistry in the presence of living cells at
28 or 37 °C, including on as challenging a system as free
halo-tryptophan, opens up new possibilities, for example:
assessing and screening, in vivo, the directed evolution of the
biosynthetic enzymes like halogenases or multifunctional
enzymes for example polyketide synthases (PKSs) and non-
ribosomal peptide synthetases (NRPSs). In such directed evolu-
tion studies, being able to assay in vivo is time efﬁcient and
maintaining the viability of the cells removes need for duplicate
plating—a time consuming process when handling the large
numbers of colonies required for such systems. Recently, Sewald
reported the use of the ﬂuorescence modulating cross-coupling
chemistry, which we have previously developed25, as a screen
for the directed evolution of a thermophilic halogenase43.
The cell compatible chemistry developed here has the potential to
signiﬁcantly open up this area, making this approach applicable
to aryl halogenases that do not originate from thermophiles.
One might also envisage utilizing the combination of synthetic
biology and synthetic chemistry, which results in a change in
ﬂuorescence to enable cell sorting of particularly productive
clones25. A further advantage of carrying out the chemistry in the
presence of the living cells is that, with the provision of additional
media, the cells can continuously produce their halo-metabolites,
such an approach could potentially be applied to bioﬁlms in ﬂow,
or possibly have dual utility in diversiﬁcation and increasing
metabolite ﬂux44. From a technical viewpoint the ability to carry
out the diversiﬁcation without an additional puriﬁcation step, in
the presence of a continuously producing biosynthetic system is
attractive. Furthermore, we ﬁnd that the enhanced lipophilicity
that the cross-coupling diversiﬁcation confers, signiﬁcantly
simpliﬁes the otherwise challenging extraction and puriﬁcation
from other media components.
Being able to use synthetic biology to generate new-to-nature
halo-natural products and carry out in-culture diversiﬁcation of
these metabolites also paves the way for chemical biological
studies in which the interactions of the diversiﬁed natural
product can be explored in the producing organisms, afﬁnity or
ﬂuorescence labeling of microbial natural products and their
subsequent tracking. For example, it would be interesting to see if
this could be applied to determine the origin and distribution of
halogenated signaling molecules. In the light of the potential
power and applicability of this approach, it is our aim to expand
the toolkit of potential orthogonal chemistries that can be
translated into the living GenoChemetic context in order to
provide new tools to monitor and better understand biological
processes or manipulating natural product targets in a precise
manner.
Methods
General information. All chemical reagents were used as received from com-
mercial sources without further puriﬁcation or prepared as described in the lit-
erature. The fully synthetic reactions were monitored by thin-layer
chromatography and the products were puriﬁed using ﬂash chromatography and
characterized using NMR and mass spectrometry. For experimental details and
characterization of all new compounds (1H/13C NMR and MS, see Supplementary
Methods and Supplementary Figs 27–50). The reactions carried out in cell culture
and involving the synthetic-biological/synthetic-chemical generation of materials
in 1 µM-500 µM quantities were followed by UPLC and liquid chromatography-
tandem mass spectrometry and compared to known standards. Additional meth-
ods for all synthetic/biosynthetic preparations and associated references are
available in the Supplementary Methods.
Cross-coupling of halo-indoles using L1-Pd catalyst. In a screw cap glass vial,
appropriate halo-indole (0.1 mmol), p-Tol-B(OH)2 (20 mg, 0.15 mmol), potassium
carbonate (42 mg, 0.3 mmol) were suspended in water-CH3CN mixture (4:1, 1.8
ml). A solution of L1-Pd in water (5 mol%, 0.2 ml) was added. The vial was closed
and stirred at 37 °C until reaction completion. Reaction was diluted with brine
(2 ml) and extracted with ethyl acetate (3 × 3–4 ml). Combined organic extract was
dried (MgSO4), ﬁltered and solvent removed under reduced pressure. The desired
product was puriﬁed by ﬂash column chromatography.
Cross-coupling of halo-tryptophans and tripeptides using L2-Pd catalyst.
In a screw cap glass vial, appropriate 5- or 7-Br-tryptophan (13 and 2, respectively,
14 mg, 0.05 mmol), p-Tol-B(OH)2 (20 mg, 0.15 mmol) and potassium carbonate
(41 mg, 0.3 mmol) were suspended in water-EtOH mixture (4:1, 1.0 ml). A solution
of L2-Pd (5 mol%) in water was added. The vial was closed and stirred at 45 °C
for 48 h. The reaction was diluted with water (2 ml) and extracted with diethyl
ether (3 × 2 ml). The aqueous layer was acidiﬁed (pH ~2–3) using 0.1 M HCl.
Solvent was removed under reduced pressure. The desired product was obtained by
puriﬁcation using gradient reversed phase chromatography (C-18, 12 g) eluting
with water-MeOH (5–95% gradient). Reactions for tripeptides were conducted
using only water as solvent.
Cross-coupling of 7-Br-tryptophan or Br-pacidamycin D in living cultures.
Appropriate culture of engineered E. coli RG-1500 or S. coelicolor RG-1104 con-
taining either 7-Br-tryptophan 2 or Br-pacidamycin D 3 (5 ml) was diluted with
phosphate buffer (45 ml, 10 mM, pH 8.5) in a sterile 250 ml ﬂask. Filter sterilized
solutions of p-tol-B(OH)2 (ﬁnal concentration 1 mM, 0.5 ml of 100 mM stock in
90% aqueous ethanol) and appropriate Pd-catalyst (ﬁnal concentration 50 or 25
µM, 250 or 125 µl of 10 mM stock in water of L3-Pd or L4-Pd) were added.
Culture ﬂasks were incubated at 37 °C (200 r.p.m., incubator throw 19 mm) for 4 h.
Cross-coupling was quenched by addition of DL-dithiothreitol (DTT, 25 µl of 1 M
stock in water). An aliquot (1 ml) was collected, cells were lysed by 5 freeze-thaw
cycles and debris removed by centrifugation (13,000 r.p.m., 16,060 × g, 5 min).
Clear supernatant was collected and analyzed by UPLC/LC-MS.
Fluorescence quantiﬁcation of 7-(p-tolyl)-tryptophan 2a (UPLC method 1).
UPLC analysis was performed on Phenomenex Kinetex phenyl-hexyl column
(2.1 μm, 2.1 × 75 mm) column eluting with 0.1% triﬂuoroacetic acid (TFA) in water
(solvent A) and methanol (solvent B). The following gradient was used: 0–0.2 min
(5% B), 0.2–5.0 min (5–95% B), 5.0–5.5 min (95% B), 5.5–5.6 (95–5% B), 5.6–6.6
(5% B). The ﬂow rate was set to 500 μl min−1 and the column temperature was
maintained at 50 °C. Detection was achieved by UV absorbance (Photodiode Array
Detector (PDA) 200–400 nm, UV 280 nm). Fluorescence emission was detected
using an excitation wavelength of 295 nm and emission wavelength of 370 nm
(gain × 1). The calibration curve for 7-(p-tolyl)-tryptophan 2a, linear in the
0.78–12.5 µM concentration range, was used for quantiﬁcation (Supplementary
Fig. 2).
Quantiﬁcation of 7-Br-tryptophan (UPLC method 2). UPLC analysis was
performed on Acquity UPLC BEH C18 (1.7 µm, 2.1 × 50 mm) column eluting with
0.1% TFA in water (solvent A) and acetonitrile (solvent B). Following gradient was
used: 0–0.5 min (5% B), 0.5–1.5 min (5% to 15% B), 1.5–9.0 min (15% B), 9.0–10.0
min (15% to 95% B), 10.0–11.0 min (95% B), 11.0–12.0 (95–5% B), 12.0–16.0
(5% B). The ﬂow rate was set to 260 μl min−1 and the column temperature was
maintained at 40 °C. Detection was achieved by UV detection (PDA 200–400 nm,
UV 280 nm). The calibration curve for 7-Br-tryptophan was linear in 15.6–500 µM
concentration range (Supplementary Fig. 9) and was used for quantiﬁcation.
LC-HRMS analysis. Liquid chromatography-high resolution mass spectrometry
(LC-HRMS) analysis of the cross-coupling reactions was conducted on a Thermo
Scientiﬁc Dionex Ultimate 3000 Rapid Separation LC system using XBridge BEH
C18 column (130 Å, 3.5 µm, 2.1 × 100 mm). The ﬂow rate was set to 0.35 ml min−1
and the column temperature was maintained at 40 °C. A generic binary gradient
elution was carried out using different ratios of eluents A (water containing 0.1%
formic acid) and B (acetonitrile). Following gradient was used: 0–0.5 min (5% B),
0.5–9.5 min (5% to 95% B), 9.5–11.5 min (95% B), 11.5–12.0 min (95% to 5% B)
and 12.0–15.0 min (5% B). The mass spectrometric analysis was performed on an
Orbitrap Velos Pro™ mass spectrometer system equipped with a Thermo Scientiﬁc
Ion MAX API source housing. The MS conditions were as follows: heated elec-
trospray ionization (HESI-II) probe, positive ionization mode, spray voltage 3.5 kV,
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capillary temperature 350 °C, normalized collision energy 35% for collision induced
dissociation, and sheath gas and auxiliary gas ﬂow rates of 35 and 10 arbitrary
units, respectively. Full scan MS spectra (from m/z 100–1000) were acquired in the
orbitrap with resolution R = 60 K.
Production of 7-Br-tryptophan 2 by engineered E. coli RG-1500. Construction
of recombinant plasmid of pSG36 for expression of the inserted halogenase system
composed of the tryptophan 7-halogenase gene (prnA) and the ﬂavin reductase
gene (ssuE) is given in Supplementary Fig. 6. A single colony of the E. coli K-12
PHL644 harboring plasmid pSG36 designated as RG-1500, from the LB agar plates
was inoculated in 5 ml of LB broth supplemented with 100 μg ml−1 ampicillin and
50 μg ml−1 kanamycin. This culture was incubated for 12 h (37 °C, 200 r.p.m.,
incubator throw of 19 mm) and was subcultured (1:100) into 200 ml LB broth
supplemented with 100 μg ml−1 ampicillin and 50 μg ml−1 kanamycin in 2 litre
bafﬂed ﬂasks. These cultures were grown to an OD600 of 0.6 (37 °C, 200 r.p.m.,
incubator throw 19 mm). The growth temperature was then reduced to 16 °C over
30 min. After cooling, the cell cultures were aliquoted into 100 ml in 2 litre bafﬂed
ﬂasks. Sodium propionate was then added, as inducer, at a ﬁnal concentration of
20 mM (from 2M stock in water) for inducing expression of the inserted halo-
genase system. A 100 ml culture, without the addition of sodium propionate, was
used as a control of the induction process. The cultures were incubated for a
further 24 h (16 °C, 200 r.p.m., incubator throw 19mm). Following this incubation
period the cultures were transferred aseptically into sterile 750 ml polypropylene
centrifuge bottles (Beckman Coulter UK Ltd.). Cells from each 100 ml culture, were
pelleted to remove LB growth media by centrifugation (8000 r.p.m., 15,970 × g, 10
min, 16 °C), washed twice with 100 ml of 10 mM phosphate buffer (pH 8.5) and re-
suspended in 45 ml CCM. Each 45 ml of cell suspension was split into 15 ml
aliquots, and 1.5 mM of L-tryptophan was added (i.e., addition of 957 μl of a 25 mM
stock in 10 mM phosphate buffer (pH 8.5) to each 15 ml of cell suspension). The
cultures were incubated for 24 h (28 °C, 200 r.p.m., incubator throw 19mm) to
enable the generation of 7-Br-tryptophan 2.
Br-pacidamycin production by engineered S. coelicolor RG-1104. PCR-
targeting45 was used to replace the kanamycin resistance gene on cosmid 2H-542
containing the pacidamycin biosynthetic genes (pac1-pac22) with a cassette for
conjugal transfer and site-speciﬁc integration into Streptomyces. The integration
cosmid was introduced into S. coelicolor M1154 by conjugal transfer from E. coli
ET12567/pUZ8002 to generate strain RG-4242, which had the expected apramy-
cin-resistant, kanamycin-sensitive phenotype consistent with integration of the
pacidamycin genes into the genome. Finally, plasmid pSG19, containing the
halogenase gene (prnA), was introduced into E. coli ET12567 carrying pUZ8002
before transfer to RG-4242 by conjugation, as previously described for S. coer-
uleorubidus8. The resulting strain, designated as RG-1104, was used for production
of brominated pacidamycins (for details, see Supplementary Methods and Sup-
plementary Figs 13–20).
Streptomycetes culturing for metabolite production. Spore stocks of the
streptomycetes to be cultured (40 µl) were used to inoculate starter culture (5 ml)
containing appropriate antibiotics. The cultures were incubated for 20 h (28 °C,
180–220 r.p.m., incubator throw 2.54 cm) before 10-fold dilution into fresh starter
media containing antibiotics. The cultures were incubated for a further 20 h (28 °C,
180–220 r.p.m., incubator throw 2.54 cm). The starter cultures were then used to
inoculate the main culture (plus antibiotics, 20-fold dilution) which were incubated
for 5–8 days (28 °C, 180–220 r.p.m., incubator throw 19 mm). Starter cultures were
grown in sterile bafﬂed ﬂasks (250 ml) whilst main cultures were grown in sterile
250 ml conical ﬂasks (for 30 ml cultures) or sterile 2 litre conical ﬂasks (for 0.5 litre
cultures). Sterile springs were placed inside the ﬂasks to prevent clumping of the
mycelium.
Cell viability analysis for cultures after cross-coupling reaction. Samples from
cross-coupling reactions of E. coli RG-1500 or S. coelicolor RG-1104 cultures,
containing 7-Br-tryptophan 2 or Br-pacidamycin D 3, treated with p-Tol-B(OH)2
(1 mM) and appropriate Pd-catalyst (50 or 25 µM, L3-Pd or L4-Pd) were incubated
for 4 h (37 °C, 200 r.p.m., incubator throw 19 mm). The cross-coupling reaction for
S. coelicolor RG-1104 cultures was quenched by addition of DTT (25 µl of 1 M
stock). An aliquot (1 ml) was used for cell viability assay. The reaction culture (30
µl) was transferred to a sterile 96-well plate containing 270 μl of sterile phosphate
buffer (10 mM, pH 8.5) obtaining a 10-fold diluted cell solution (1 × 10−1 dilution).
In this fashion, a serial dilution was performed to give the ﬁnal concentration
1 × 10−6; 100 μl of the ﬁnal dilution were spread on LB-agar plates containing
50 µg ml−1 kanamycin or ISP2 agar plates, respectively. The plates were incubated
in a static incubator at 37 °C overnight and colony forming units were counted.
In parallel, this process was repeated for a control reaction culture, without
treatment with both the Pd-catalyst and p-Tol-B(OH)2. The experiments were
performed in triplicate (Supplementary Figs 12 and 26).
Data availability. Data supporting the ﬁndings in this study are available within
the article (and its supplementary information ﬁles) and from the corresponding
author upon reasonable request.
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